Welcome to our dedicated page for Lexaria Bioscience news (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience stock.
Lexaria Bioscience Corp. develops and licenses DehydraTECH, a patented oral drug delivery formulation and processing platform designed to improve how active pharmaceutical ingredients enter the bloodstream. News about LEXX centers on GLP-1 drug delivery research, DehydraTECH-semaglutide compositions, preclinical and human study updates, intellectual property activity, and pharmaceutical partner evaluations under material transfer arrangements.
Company updates also cover Lexaria's investor communications, oral drug delivery market commentary, and applications of DehydraTECH across pharmaceuticals, nutraceuticals, over-the-counter products, and consumer formats. Recurring themes include bioabsorption, tolerability, blood-brain-barrier delivery, research laboratory activity, and the company's IP licensing business model.
Lexaria Bioscience (NASDAQ:LEXX) released the second episode of its investor series on May 7, 2026, featuring CEO Rich Christopher discussing a Material Transfer Agreement extension through year-end 2026 with a global pharmaceutical partner and the company’s 2026 GLP-1 research priorities. The episode outlines plans to generate clinical data this year and continued business development activity tied to DehydraTECH and oral drug delivery programs.
Additional episodes will cover the clinical pipeline, intellectual property, and commercial strategy.
Lexaria (NASDAQ:LEXX) updated progress on Human Pilot Study #7 (GLP-1-H26-7), which will compare two DehydraTECH-semaglutide (DHT-sema) compositions to Wegovy tablets under fasted conditions.
Ethics submissions are filed, tablet manufacturing is complete, third-party QC testing is underway, and Lexaria anticipates Pre-Dosing Tasks done by early June with dosing expected mid‑June; the Study is fully funded.
Lexaria (NASDAQ:LEXX) launched Reformulated: Into the Mainstream, an ongoing investor video series to increase transparency and engagement with shareholders.
The inaugural episode features CEO Rich Christopher discussing the DehydraTECH platform, applicability across GLP-1 therapies, CBD and antivirals, the ~$75 billion GLP-1 market in 2025, completion of five human GLP-1 studies, and outlicensing activity under an active Material Transfer Agreement with a global pharmaceutical company.
Lexaria (NASDAQ:LEXX) announced an extension of its Material Transfer Agreement with a pharmaceutical company through December 31, 2026 to allow review of Lexaria's 2026 GLP-1 R&D results.
The extension keeps the temporary exclusive license active, allows continued collaboration talks, and supports ongoing Human Study #7 and Animal Studies #1 and #2, all funded by existing corporate resources with results expected in Q3–Q4 2026.
Lexaria Bioscience (NASDAQ:LEXX) announced contracts with a CRO to run Animal Study #2 (GLP-1-A26-2) evaluating DehydraTECH formulations with next-generation GLP-1 drugs amycretin and retatrutide. The 18-arm study will measure 24-hour pharmacokinetics and tolerability, compare pills versus capsules, and test alternative enhancers such as sodium caprate. Dosing is expected within 30 days and the Study is fully funded from existing resources.
Lexaria (NASDAQ:LEXX) highlights rapid growth in the oral GLP-1 pill market and potential demand for its DehydraTECH delivery platform. Key industry signals include 600,000 Wegovy pill prescriptions in the first two months and analyst GLP-1 forecasts ranging up to $180B by mid-2030s. Lexaria reports DehydraTECH performance with semaglutide, tirzepatide, and liraglutide and plans 2026 R&D to explore retatrutide and amycretin applicability while engaging pharmaceutical partners.
Lexaria Bioscience (NASDAQ:LEXX) has contracted a CRO to run its 2026 animal Study #1 (GLP-1-A26-1) to test DehydraTECH-semaglutide and DehydraTECH-CBD formulations and pursue new intellectual property claims.
The study plans 8–11 arms in Sprague-Dawley rats, blood sampling over an 8–24-hour post-dose window, brain biodistribution measures, reference arms, dosing targeted to begin in approximately 60 days, and is fully funded from existing corporate resources.
Lexaria (Nasdaq:LEXX) applauded the FDA approval of Eli Lilly's oral GLP-1 drug Foundayo for adult weight control on April 7, 2026. Lexaria highlights expanding oral GLP-1 choices (now three brands) and cites Foundayo's 72-week average weight loss of 27.3 lb (12.4%).
Lexaria notes DehydraTECH has shown side-effect reductions (Study GLP-1-H24-4: 47.9% fewer adverse events vs Rybelsus) and holds 65 issued patents, with additional GLP-1 testing planned in 2026.
Lexaria (NASDAQ:LEXX) signed contracts with a CRO to run Human Pilot Study #7 (GLP-1-H26-7) evaluating two oral DehydraTECH-semaglutide (DHT-sema) formulations versus Wegovy tablets.
The 5-week, three-arm parallel study will test tablet and capsule DHT-sema with SNAC under fasted conditions, aiming to assess safety, tolerability and pharmacokinetics; ethics approval is pending and the study is fully funded from corporate resources.
Lexaria (Nasdaq:LEXX) announced five new patents across Japan and Australia, expanding its IP for hypertension, epilepsy and diabetes treatments tied to its DehydraTECH delivery platform.
New grants: two Japan hypertension patents (issued Feb 20, 2026; term to Apr 25, 2043), one Australian epilepsy patent (issued Feb 12, 2026; term to Feb 20, 2044), and two Australian diabetes patents (issued Feb 12, 2026; term to Dec 3, 2044). Lexaria cites a Phase 1b human study that supported DehydraTECH combined with GLP-1 drugs.